Insider Selling: Natera (NASDAQ:NTRA) CEO Sells 14,083 Shares of Stock

Key Points

• Natera CEO Steven Leonard Chapman sold 14,083 shares of stock on October 1st for a total of $2,253,280, resulting in an 8.38% decrease in his ownership.
• The company reported a Q2 net loss of ($0.74) per share, missing the consensus estimate, but revenue increased by 32.2% year-over-year.
• Natera has a current market cap of $22.18 billion and is anticipated to have a consensus target price of $192.88 according to analysts.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 14,083 shares of the company's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $160.00, for a total value of $2,253,280.00. Following the sale, the chief executive officer owned 154,072 shares of the company's stock, valued at approximately $24,651,520. The trade was a 8.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, September 30th, Steven Leonard Chapman sold 9,109 shares of Natera stock. The shares were sold at an average price of $162.05, for a total value of $1,476,113.45.
• On Tuesday, September 2nd, Steven Leonard Chapman sold 5,079 shares of Natera stock. The shares were sold at an average price of $166.53, for a total value of $845,805.87.
• On Friday, August 1st, Steven Leonard Chapman sold 5,807 shares of Natera stock. The stock was sold at an average price of $132.88, for a total value of $771,634.16.
• On Monday, July 28th, Steven Leonard Chapman sold 6,092 shares of Natera stock. The stock was sold at an average price of $139.81, for a total value of $851,722.52.
• On Monday, July 21st, Steven Leonard Chapman sold 1,622 shares of Natera stock. The shares were sold at an average price of $139.29, for a total value of $225,928.38.

Natera Price Performance

Shares of NTRA traded up $0.64 during mid-day trading on Wednesday, hitting $161.61. The stock had a trading volume of 1,583,819 shares, compared to its average volume of 1,079,070. The firm has a market cap of $22.18 billion, a P/E ratio of -84.61 and a beta of 1.74. The business has a fifty day moving average price of $160.22 and a 200-day moving average price of $156.35. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same quarter last year, the company posted ($0.30) earnings per share. Natera's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently bought and sold shares of NTRA. Wealth Enhancement Advisory Services LLC increased its stake in shares of Natera by 79.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 19,493 shares of the medical research company's stock worth $3,086,000 after acquiring an additional 8,635 shares during the period. GAMMA Investing LLC grew its position in shares of Natera by 18,607.6% in the first quarter. GAMMA Investing LLC now owns 119,916 shares of the medical research company's stock valued at $16,957,000 after purchasing an additional 119,275 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Natera by 10.9% during the first quarter. Rhumbline Advisers now owns 153,402 shares of the medical research company's stock valued at $21,693,000 after buying an additional 15,121 shares during the period. Harbor Investment Advisory LLC lifted its stake in shares of Natera by 419.2% during the first quarter. Harbor Investment Advisory LLC now owns 1,677 shares of the medical research company's stock valued at $237,000 after buying an additional 1,354 shares during the period. Finally, Merit Financial Group LLC raised its stake in Natera by 168.7% during the first quarter. Merit Financial Group LLC now owns 9,369 shares of the medical research company's stock worth $1,325,000 after purchasing an additional 5,882 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of analyst reports. Stephens reaffirmed an "overweight" rating and set a $183.00 target price on shares of Natera in a research note on Friday, August 15th. Piper Sandler reissued an "overweight" rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Royal Bank Of Canada set a $268.00 target price on Natera and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research report on Monday, July 28th. Finally, Wells Fargo & Company assumed coverage on Natera in a research report on Monday, September 22nd. They set an "equal weight" rating and a $175.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Natera has a consensus rating of "Buy" and a consensus price target of $192.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.